Inventor · disambiguated record
Anthony Rossomando
Also filed as: ROSSOMANDO ANTHONY · ROSSOMANDO ANTHONY JOHN
16 granted patents·12 pending applications·128 citations·filing 2003–2021
92Inventor score
Top patents by PatentIndex Score
28 records- 0194US7655463B2Methods of activating RET receptor tyrosine kinase using neurotrophic factorsBIOGEN IDEC INC·Filed 2008·Granted Feb 2, 2010·24 cites·16 claims
- 0294US7358228B2Methods of treating pain using neurotrophic factorsBIOGEN IDEC INC·Filed 2006·Granted Apr 15, 2008·23 cites·29 claims
- 0392US7442370B2Polymer conjugates of mutated neublastinBIOGEN IDEC INC·Filed 2003·Granted Oct 28, 2008·35 cites·68 claims
- 0489US7276580B2Neurotrophic factorsNSGENE AS·Filed 2003·Granted Oct 2, 2007·24 cites·14 claims
- 0585US8119114B2Polymer conjugates of mutated neublastinSAH DINAH WEN-YEE·Filed 2008·Granted Feb 21, 2012·3 cites·60 claims
- 0681US8722862B2Refolding transforming growth factor beta family proteinsROSSOMANDO ANTHONY·Filed 2005·Granted May 13, 2014·3 cites·28 claims
- 0781US8217146B2Neurotrophic factors and methods of use thereofSAH DINAH W Y·Filed 2009·Granted Jul 10, 2012·4 cites·33 claims
- 0879US10047150B2Anti-neublastin antibodies and uses thereofGLORIANA THERAPEUTICS SARL·Filed 2015·Granted Aug 14, 2018·3 cites·9 claims
- 0978US8263553B2Neublastin variantsROSSOMANDO ANTHONY·Filed 2005·Granted Sep 11, 2012·3 cites·219 claims
- 1075US8642732B2Polymer-conjugated glycosylated neublastinSAH DINAH WEN-YEE·Filed 2012·Granted Feb 4, 2014·2 cites·22 claims
- 1170US8329655B2Methods for increasing vascularizationROSSOMANDO ANTHONY·Filed 2008·Granted Dec 11, 2012·2 cites·31 claims
- 1267US8163875B2Polymer conjugated glycosylated neublastinSAH DINAH WEN-YEE·Filed 2004·Granted Apr 24, 2012·2 cites·48 claims
- 1358US8969042B2Refolding transforming growth factor beta family proteinsBIOGEN IDEC INC·Filed 2014·Granted Mar 3, 2015·0 cites·36 claims
- 1457US2010056440A1Compositions and methods for administering gdnf ligand family proteinsBIOGEN IDEC INC·Filed 2007·Application pending·0 cites
- 1557US2011135648A1Anti-neublastin antibodies and uses thereofBIOGEN IDEC INC·Filed 2008·Application pending·0 cites
- 1655US2013109624A1Novel neurotrophic factorsSAH DINAH W Y·Filed 2012·Application pending·0 cites
- 1749US9138461B2Compositions and methods for increasing vascularizationBIOGEN IDEC INC·Filed 2012·Granted Sep 22, 2015·0 cites·15 claims
- 1849US2023312684A1Neuropilin and angiotensin converting enzyme 2 fusion peptides for treating viral infectionsPINETREE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1947US2013096065A1Neublastin variantsROSSOMANDO ANTHONY·Filed 2012·Application pending·0 cites
- 2045US10328125B2Treatments for neurological disordersROSSOMANDO ANTHONY·Filed 2007·Granted Jun 25, 2019·0 cites·19 claims
- 2144US2013164329A1Cell-based methods and reagentsROSSOMANDO ANTHONY·Filed 2011·Application pending·0 cites
- 2239US2013196410A1Compositions and methods for modifying the glycosylation pattern of a polypeptideROSSOMANDO ANTHONY·Filed 2011·Application pending·0 cites
- 2338US2013164851A1Gene amplification and transfection methods and reagents related theretoROSSOMANDO ANTHONY·Filed 2011·Application pending·0 cites
- 2438US2012282670A1Compositions and methods for enhancing production of a biological productROSSOMANDO ANTHONY·Filed 2010·Application pending·0 cites
- 2537US2014004565A1Cell-based bioprocessingROSSOMANDO ANTHONY·Filed 2010·Application pending·0 cites
- 2637US2014099666A1Compositions and methods for enhancing production of a biological productROSSOMANDO ANTHONY·Filed 2010·Application pending·0 cites
- 2736US2014154783A1BioprocessingROSSOMANDO ANTHONY·Filed 2010·Application pending·0 cites
- 2829US10413597B2Methods of treating Mucopolysaccharidosis IIIB (MPSIIIB)ALEXION PHARMA INC·Filed 2015·Granted Sep 17, 2019·0 cites·10 claims
Join the waitlist — get patent alerts
Get an alert when Anthony Rossomando files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →